

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津發展控股有限公司
TIANJIN DEVELOPMENT HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), an indirect non-wholly owned subsidiary of the Company, has published an announcement on the website of Shenzhen Stock Exchange (www.szse.cn) in respect of its preliminary results for the year of 2025, full text of which is reproduced in the attachment of this announcement.

As at the date of this announcement, the Company indirectly holds approximately 34.12% of the issued share capital of Lisheng Pharmaceutical.

By Order of the Board
Tianjin Development Holdings Limited
Teng Fei
Chairman and Executive Director

Hong Kong, 10 March 2026

As at the date of this announcement, the Board of the Company consists of Mr. Teng Fei, Dr. Zhai Xinxiang, Mr. Xia Binhui, Mr. Sun Lijun, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter**, Mr. Lau Ka Keung** and Mr. Sin Hendrick**.*

* *non-executive director*

** *independent non-executive director*

TIANJIN LISHENG PHARMACEUTICAL CO., LTD.

PRELIMINARY RESULTS ANNOUNCEMENT FOR 2025

The Company and all the members of the Board warrant the truthfulness, accuracy and completeness of the disclosure of such information, and there are no false statements, misleading statements nor material omissions.

CAUTION: The financial information for 2025 contained in this announcement is only the preliminary accounting data that has been reviewed by the internal audit department of the Company but has not been audited by the audit firm. There may be discrepancies between the information contained herein and the final data to be disclosed in the 2025 annual report. Investors are advised to beware of investment risks which may result therefrom.

1. KEY FINANCIAL INFORMATION AND INDICATORS FOR 2025

Unit: RMB

Item	The reporting period	For the same period last year	Increase / (Decrease)
Total revenue from operations	1,392,663,934.63	1,336,154,449.87	4.23%
Profit from operations	469,957,828.86	221,650,720.22	112.03%
Total profit	456,432,176.66	215,948,800.36	111.36%
Net profit attributable to the shareholders of the Company	418,365,973.76	184,528,445.53	126.72%
Net profit after extraordinary items attributable to the shareholders of the Company	169,084,905.34	102,997,849.18	64.16%
Basic earnings per share	1.62	0.72	125.00%
Weighted average return on net assets	8.56%	3.74%	4.82%
	As at the end of the reporting period	As at the beginning of the reporting period	Increase / (Decrease)
Total assets	5,584,429,772.98	5,785,511,812.28	-3.48%
Owners' equity attributable to the shareholders of the Company	4,630,138,992.15	4,769,916,090.81	-2.93%
Share capital	257,586,843.00	257,895,388.00	-0.12%
Net assets per share attributable to the shareholders of the Company	17.98	18.50	-2.81%

2. EXPLANATION OF OPERATING RESULTS AND FINANCIAL PERFORMANCE

1. In 2025, the Company achieved a total revenue of RMB1,392,663,934.63, an increase of 4.23% over last year.

2. The Company has expanded its market and increased product sales, in addition to the dividend contribution from an equity instrument, both total profit and net profit attributable to the shareholders of the Company recorded significant year-on-year growth. In 2025, the Company recorded total profit of RMB456,432,176.66, an increase of 111.36% over last year and net profit after extraordinary items attributable to the shareholders of the Company of RMB169,084,905.34, an increase of 64.16% over last year.

3. The fair value changes of equity instrument resulted in a decrease in both the owners' equity attributable to the shareholders of the Company and the net assets value per share.

3. EXPLANATION OF VARIANCES WITH THE PREVIOUS EXPECTED RESULTS DISCLOSURE

The financial data disclosed in this preliminary results announcement are within the range of the indicative results announcement as previously disclosed and there is no difference from the previous expected results disclosure.

4. CAUSES OF PERFORMANCE LEAKAGE AND ANALYSIS OF STOCK PRICE ABNORMAL FLUCTUATION

Not applicable.

5. DOCUMENTS AVAILABLE FOR INSPECTION

1. The comparative balance sheet and income statement signed and sealed by the legal representative of the Company, the person in charge of the accounting affairs of the Company and the head of accounting department of the Company;

2. Other documents required by Shenzhen Stock Exchange.

The Board of Directors of
Tianjin Lisheng Pharmaceutical Co., Ltd.
10 March 2026